

6 April 2023

Treatment of Urothelial and Colorectal Cancer

Q1. How many urothelial cancer patients have been treated in the past 3 months with the following agents:

- Avelumab : 11
- Atezolizumab : 9
- Carboplatin with Gemcitabine : 15
- Carboplatin single or in any other combination : <4
- Cisplatin with Gemcitabine : 5
- Cisplatin single or in any other combination : <5
- Nivolumab : <5
- Pembrolizumab : <5
- Any other regimen including Paclitaxel : <5
- Any other chemotherapy regimen : <5
- Other active systemic anti-cancer therapy : <5
- Palliative care only : Not available via RISOH

Q2. How many colorectal cancer [CRC] patients have been treated in the past 3 months with the following agents:

- Aflibercept : <5
- Bevacizumab : 8
- Capecitabine : 186
- CAPIRI : <5
- CAPOX (XELOX)
- Cetuximab in combination with FOLFIRI: 28
- Cetuximab in combination with FOLFOX : 6
- Cetuximab not in combination with FOLFIRI or FOLFOX : 12
- Irinotecan only : <5
- FOLFIRI : 63
- FOLFOX : 91
- Fluorouracil (5FU) only : <5
- Oxaliplatin only : <5
- Panitumumab in combination with FOLFIRI : <5
- Panitumumab in combination with FOLFOX : <5
- Panitumumab not in combination with FOLFIRI or FOLFOX : <5
- Pembrolizumab : 14
- Nivolumab : 5
- Raltitrexed : <5
- Ramucirumab : <5



6 April 2023

- Regorafenib : <5
- Sorafenib : <5
- Other active systemic anti-cancer therapy Oxalaplatin & Raltitrexed (TOMOX) : 5 , Mitomycin C & Capcitabine : 6, Longsurf : 36, Irinotecan & Capcitabine : 13 & Irinotecan & Raltitrexed : <5
- Palliative care only : No available via RISOH